|
|
|
|
|
08.04.26 - 13:24
|
Up 8%: what’s going on with Lloyds shares today? (Fool)
|
|
|
Dr James Fox takes a closer look at one of the stock market's biggest gainers on Wednesday 8 April after the US and Iran agreed a ceasefire.
The post Up 8%: what's going on with Lloyds shares today? appeared first on The Motley Fool UK....
|
|
|
|
|
08.04.26 - 13:18
|
Telia to Deploy Seamless OS Following Acquisition of Telness Operator (Business Wire)
|
|
|
STOCKHOLM--(BUSINESS WIRE)--$telia.st #MNO--Today, Nordic Communications Group AB, parent company of Telness Tech, announced it will divest its mobile virtual network operator (MVNO) Telness to Telia in Sweden. As part of the transaction, Telness will sign a long-term agreement with Telness Tech for continued use of the Seamless OS technology platform, ensuring a smooth digital customer experience. At closing, Telia will become the first mobile network operator (MNO) to deploy Seamless OS.
"For Seamless OS to be brought into an MNO environment such as Telia's is a defining moment for us. Our platform was initially developed and proven within Telness, enabling it to become one of Europe's most digitally advanced operators. With Telia's acquisition of Telness, the technology will continue to serve the end customers. Telness will retain its strong digital experience, with the added significant scaling and marketing capabilities that Telia brings," says Martina Klingvall, Founder and CEO, Telness...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.04.26 - 13:06
|
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer (Business Wire)
|
|
|
Financing co-led by Frazier Life Sciences and Novartis Venture Fund with significant participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund and Astellas Venture ManagementSAN DIEGO--(BUSINESS WIRE)--Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer, today announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management and Alexandria Venture Investments. Concurrent with the financing, Daniel Estes, Ph.D., from Frazier Life Sciences, Michal Silverberg from Novartis Venture Fund, Josh Richardson, M.D., from Life Sciences at Goldman Sachs ...
|
|
|
|
|
|
|
|
|
|
|
|
Alle News zu Europa 5926.75 +3.87% (E.St.50 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
